Answers are grounded in this paper and cite their sources.
We validated a previously identified CSF biosignature and showed that refinement of this biosignature by incorporation of other biomarkers diagnosed TBM with high accuracy. Incorporation of these biomarkers into a point-of-care or bedside diagnostic test platform may result in the improved management of TBM in children.
No takes yet. Share an insight, caveat, or question.
Manyelo et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: